---
layout: post
title: "Pulmonary Tuberculosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:52 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-27186
original_published: 2022-12-15 00:00:00 +0000
significance: 8.00
---

# Pulmonary Tuberculosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 15, 2022 00:00 UTC
**Document Number:** 2022-27186

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Pulmonary Tuberculosis: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of new antibacterial drugs for the treatment of pulmonary tuberculosis (TB). This draft guidance does not address the development of drugs for latent TB infection or for extrapulmonary TB. This draft guidance revises and replaces the draft guidance for industry of the same name published on November 6, 2013.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/15/2022-27186/pulmonary-tuberculosis-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-27186

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
